Effective and Safe Glycemic Control in Patients with Diabetes Mellitus Type 2 when Using Fixed Combination of Oral Hypoglycemic Agents

Main Article Content

V.I. Pankiv


Diabetes mellitus (DM) type 2 is associated not only with hyperglycemia, but also with an increased atherogenic risk. Due to this glucose-lowering therapy should be not only effective, but also safe regarding the development of micro- and macrovascular complications. To intensify hypoglycemic therapy in patients who do not achieve disease compensation at monotherapy with metformin or sulfonylureas, combination of these two oral hypoglycemic agents is considered reasonable. One of these combinations, that can effectively, safely and economically feasible to achieve therapeutic objectives of treatment of diabetes mellitus type 2, is considered fixed combination of metformin and glibenclamide (Glibomet). The most important advantages of fixed combinations include low doses of each drug component without loss of anti-diabetic efficacy, a significant decrease in side effects from the gastrointestinal tract, minimizing the risk of hypoglycemic reactions and others. A fixed combination of glibenclamide and metformin allows simple, flexible regimen increases compliance in patients, providing psychological comfort and improves quality of life.

Article Details

How to Cite
Pankiv, V. “Effective and Safe Glycemic Control in Patients With Diabetes Mellitus Type 2 When Using Fixed Combination of Oral Hypoglycemic Agents”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), no. 4.52, May 2013, pp. 11-16, doi:10.22141/2224-0721.4.52.2013.84378.
To practicing Endocrinologists


Аметов А.С., Соловьева О.Л. Сердечно-сосудистые осложнения при сахарном диабете: патогенез и пути коррекции // РМЖ. Эндокринология. — 2011. — № 27. — С. 1694-1699.

Аметов A.C., Козедубова И.В. Комбинированная терапия как особенность управления сахарным диабетом типа 2 у кардиальных больных // Болезни сердца и сосудов. — 2007. — № 2. — С. 26-31.

Дедов И.И. Сахарный диабет: развитие технологий в диагностике, лечении и профилактике (пленарная лекция) // Сахарный диабет. — 2010. — № 3. — С. 6-13.

Примерный перечень ВОЗ Основных лекарственных средств. 15-й перечень, март 2007. www.who.int/medicines/ publications/EML15.pdf

Смирнова Е.Н., Степанова А.В. Комбинированная терапия сахарного диабета: место фиксированных комбинаций // Эндокринология. — 2011. — № 5. — С. 16-20.

Чукаева И.И. Изучение влияния воспаления на прогноз острой кардиоваскулярной патологии. Пути коррекции // Российский кардиологический журнал. — 2009. — № 5. — С. 30-34.

Bolen S., Feldman L., Vassy J. et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus // Ann. Intern. Med. — 2007. — Vol. 147. — P. 386-399.

Eurich D.T., McAlister F.A., Blackburn D.F. et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review // BMJ. — 2007. — Vol. 335. — P. 497.

Gangji A.S., Cukierman T., Gerstein H.C. et al. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin // Diabet. Care. — 2007. — Vol. 30. — P. 389-394.

Gerstein H.C, Miller M.E., Byington R.P. et al. Effects of intensive glucose lowering in type 2 diabetes // N. Engl. J. Med. — 2008. — Vol. 358. — P. 2545-2559.

Homko C.J., Sivan E., Reece A.E. Is there a role for oral antihyperglycemics in gestational diabetes and type 2 diabetes during pregnancy? // Treat. Endocrinol. — 2004. — Vol. 3. — P.133-139.

Kahler K.H., Rajan M., Rhoads G.G. et al. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration // Diabet. Care. — 2007. — Vol. 30. — P. 1689-1693.

Patel A., MacMahon S., Chalmers J. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. — 2008. — Vol. 358, № 24. — P. 2560-2572.

Saenz A., Fernandez-Esteban I., Mataix A. et al. Metformin monotherapy for type 2 diabetes mellitus // Cochrane Database Syst. Rev. — 2005. — Vol. 20, 3. — CD002966.

Schramm Т.К., Gislason G.H., Vaag A. et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study // Eur. Heart J. — 2011. — Vol. 32, № 15. — P. 1900-1908.

Selvin E., Bolen S., Yeh H.C. et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review // Arch. Intern. Med. — 2008. — Vol. 168, № 19. — P. 2070-2080.

Shimabukuro M., Higa N., Takasu N. Comparison of the antioxidant and vascular effects of gliclazide and glibenclamide in Type 2 diabetic patients: a randomized crossover study // J. Diabet. Complicat. — 2006. — Vol. 20. — P. 179-183.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 11 12 > >>